Rznomics Inc. (KOSDAQ:476830)

Market Cap	2.21T
Revenue	n/a
Net Income	n/a
Shares Out	13.76M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,142,354
Average Volume	2,326,102
Open	160,400
Previous Close	162,000
Day's Range	153,300 - 166,500
52-Week Range	90,000 - 176,800
Beta	n/a
RSI	n/a
Earnings Date	n/a

About Rznomics

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for Glioblastoma; RZ-003, which is in discovery stage for Alzheimer; RZ-004, a pre-clinical product for Retinitis Pigmentosa; and RZ-005, a discovery stage product to treat Rett Syndrome. Rznomics Inc. was incorporated in 2017 and is head quartered in Seongnam, ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476830